126 related articles for article (PubMed ID: 37695273)
1. The evolution of payer management of oncology drugs in the United States between 2017 and 2022.
Runyan A; Yi J; Honcz J
J Manag Care Spec Pharm; 2023 Oct; 29(10):1138-1149. PubMed ID: 37695273
[No Abstract] [Full Text] [Related]
2. Current and Future Oncology Management in the United States.
Runyan A; Banks J; Bruni DS
J Manag Care Spec Pharm; 2019 Feb; 25(2):272-281. PubMed ID: 30698085
[TBL] [Abstract][Full Text] [Related]
3. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
4. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
5. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
6. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
Schafer J; Galante D; Shafrin J
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
[TBL] [Abstract][Full Text] [Related]
7. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers.
Lopata E; Terrone C; Gopalan A; Ladikos N; Richardson T
J Manag Care Spec Pharm; 2021 Jun; 27(6):706-713. PubMed ID: 33586514
[No Abstract] [Full Text] [Related]
10. Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.
Greenapple R
Am Health Drug Benefits; 2012 Jul; 5(4):242-53. PubMed ID: 24991323
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
14. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers.
Greenapple R
Am Health Drug Benefits; 2012 Mar; 5(2):83-92. PubMed ID: 24991313
[TBL] [Abstract][Full Text] [Related]
15. Payer perceptions and use of value assessment tools in the United States.
Westrich K; Hydery T; Dharbhamalla V; Buelt L; Zheng C; Loo V; Graff J
J Manag Care Spec Pharm; 2023 May; 29(5):582-588. PubMed ID: 37121246
[No Abstract] [Full Text] [Related]
16. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
17. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
[TBL] [Abstract][Full Text] [Related]
18. Rapid expansion of new oncology care delivery payment models: results from a payer survey.
Greenapple R
Am Health Drug Benefits; 2013 Jul; 6(5):249-56. PubMed ID: 24991361
[TBL] [Abstract][Full Text] [Related]
19. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
